title: Have drug combinations supplanted stem cell transplantation in myeloma?
abstract: The introduction of proteasome inhibitor and immunomodulatory drugs has considerably changed the treatment paradigm of multiple myeloma. Autologous stem cell transplantation (ASCT) is superior to conventional chemotherapy and is considered the standard of care for patients younger than 65 years. Nevertheless, the favorable results shown by multidrug inductions, consolidations, and long-term maintenance approaches have challenged the role of ASCT. This article provides an overview of recent and ongoing clinical trials and aims to define the role of ASCT in the era of novel agents.
authors.affiliation: Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy. appalumbo@yahoo.com
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.forename: Federica
authors.initials: F
authors.lastname: Cavallo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D018572:Disease-Free Survival; D004358:Drug Therapy / Q000379:methods / Q000639:trends; D005260:Female; D023281:Genomics; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy*; D016016:Proportional Hazards Models; D011719:Pyrazines / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib